glp 1 and gip agonist The activity of GLP-1 for Type 2 Diabetes and Obesity Two incretin hormones GLP-1 and

Initially, it was a modest tool in the diabetes arsenal: enhanced insulin release, suppressed glucagon, slowed gastric emptying

Some GLP-1 medications come with additional FDA-approved benefits

Targeting the incretin/glucagon system with agonists Figure 1: Schematic representation of the effects of multi-agonists targeting the receptors for GLP-1/Glucagon, GLP-1/GIP and GLP-1/GIP/Glucagon [28] In Part I of our blog we reported on dual receptor agonists targeting the incretin/glucagon system to treat obesity and type 2 diabetes mellitus with high efficacy

The preferential accumulation of visceral fat is influenced by genetics, hormonal factors (particularly cortisol and sex hormones), dietary patterns, physical inactivity, and aging

Compounded versions are not FDA-approved

Claims are checked against primary regulatory, trial, label, and public-health sources where available